For research use only. Not for therapeutic Use.
UMB298 is a potent and selective CBP/P300 bromodomain inhibitor[1].
UMB298 (0.01~10 μM; 50 days; MOLM13 and MM cells) inhibits cells growth[1].
UMB298 (1~10 μM; 2 hours; MOLM13 cells) reduces the H3K27ac level similar to CBP30 and causes MYC depletion as a signature of CBP inhibition in acute myeloid leukemia[1].
UMB298 (3 μM; 2hours; MOLM13 cells) down-regulates MYC expression[1].
| Catalog Number | I044444 |
| CAS Number | 2266569-73-5 |
| Synonyms | 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-N-cyclohexyl-7-(3,5-dimethyl-1,2-oxazol-4-yl)imidazo[1,2-a]pyridin-3-amine |
| Molecular Formula | C27H31ClN4O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C27H31ClN4O2/c1-17-26(18(2)34-31-17)20-13-14-32-25(16-20)30-23(27(32)29-21-7-5-4-6-8-21)11-9-19-10-12-24(33-3)22(28)15-19/h10,12-16,21,29H,4-9,11H2,1-3H3 |
| InChIKey | NZXSWCLCRDCHGN-UHFFFAOYSA-N |
| SMILES | CC1=C(C(=NO1)C)C2=CC3=NC(=C(N3C=C2)NC4CCCCC4)CCC5=CC(=C(C=C5)OC)Cl |
| Reference | [1]. Muthengi A, et al. Development of Dimethylisoxazole-Attached Imidazo[1,2-a]pyridines as Potent and Selective CBP/P300 Inhibitors. J Med Chem. 2021;64(9):5787-5801. |
